Valuation: Relmada Therapeutics, Inc.

Market Cap 57Cr 50Cr 46Cr 43Cr 81Cr 5.46TCr 82Cr 547.62Cr 214.08Cr 2.73TCr 215.46Cr 210.74Cr 9.04TCr P/E 2026 *
-6.62x
P/E 2027 * -5.52x
Enterprise Value 57Cr 50Cr 46Cr 43Cr 81Cr 5.46TCr 82Cr 547.62Cr 214.08Cr 2.73TCr 215.46Cr 210.74Cr 9.04TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 27/10/2020
Chief Executive Officer 65 01/04/2012
Director of Finance/CFO 61 09/01/2020
Director TitleAgeSince
Director/Board Member 65 01/04/2012
Chairman 81 15/06/2017
Director/Board Member 67 12/11/2015
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+8.91% - - 57Cr
+10.00%+14.90%+53.89%+87.07% 6.25TCr
+1.92%-4.56%+23.57%+67.43% 5.24TCr
-0.98%-1.19%-16.98%-14.21% 2.31TCr
+0.30%-5.17%-11.23%+349.07% 2.14TCr
+0.31%+0.72%+31.41%-25.99% 1.78TCr
+4.29%+8.97%+200.03%+341.85% 1.55TCr
+2.08%-1.17%+13.58%+612.75% 1.47TCr
+1.71%-0.90%+52.13%+176.27% 1.41TCr
+4.16%+4.44%+444.12%+183.06% 1.26TCr
Average +2.34%+0.99%+87.84%+197.48% 2.6TCr
Weighted average by Cap. +3.72%+1.83%+60.50%+148.40%

Financials

2026 *2027 *
Net sales - -
Net income -8.2Cr -7.12Cr -6.64Cr -6.1Cr -12Cr -780.39Cr -12Cr -78Cr -31Cr -390.11Cr -31Cr -30Cr -1.29TCr -11Cr -9.39Cr -8.75Cr -8.04Cr -15Cr -1.03TCr -15Cr -103.19Cr -40Cr -514.09Cr -41Cr -40Cr -1.7TCr
Net Debt - -
Logo Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.470USD
Average target price
12.67USD
Spread / Average Target
+131.57%

Quarterly revenue - Rate of surprise